All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

11

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 11 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Omeprazole

Omeprazole

D$367M-13%7,509,766$49$0.17
Esomeprazole Magnesium

Esomeprazole Magnesium

D$124M-28%741,842$168$0.64
Omeprazole-Sodium Bicarbonate

Omeprazole/Sodium Bicarbonate

D$122M-30%18,255$6,704$28.61
Nexium

Esomeprazole Magnesium

D$59.7M-20%20,438$2,922$8.85
Naproxen-Esomeprazole Mag

Naproxen/Esomeprazole Mag

D$15.9M-40%3,550$4,481$14.55
Konvomep

Omeprazole/Sodium Bicarbonate

D$4.5M+133%1,959$2,280$1.41
Zegerid

Omeprazole/Sodium Bicarbonate

D$3.3M-62%252$12,949$105.22
Prilosec

Omeprazole Magnesium

D$3.2M0%823$3,928$15.25
Talicia

Omeprazole/Amoxicill/Rifabutin

D$2.6M-21%3,265$802$4.68
Vimovo

Naproxen/Esomeprazole Mag

D$268K-92%26$10,301$35.99
Esomeprazole Sodium

Esomeprazole Sodium

D$31K+24%n/an/a$20.35

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.